Matrix metalloproteinases in diseases of the gastrointestinal tract;Metaloproteinasas de matriz en enfermedades del tracto gastrointestinal

Gastroenterologia y Hepatologia

Volumn 27, Issue 8, 2004, Pages 491-497

  Medina, C ^a   Santana, A ^a   Quintero, E ^a   Radomski, M W ^b   Guarner, F ^c  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MMI 166; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

DIGESTIVE SYSTEM CANCER; ENTERITIS; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; GASTROINTESTINAL DISEASE; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 6344294706     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13065956     Document Type: Review

References (63)

1. Woessner FJR. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.
2. Woessner FJR. Literature on vertebrate matrix metalloproteinases and their tissue inhibitors. Matrix 1991;1(Suppl 1):425-501.
3. Matrisian LM. The matrix-degrading metalloproteinases. BioEssays 1992;14:455-63.
4. Nagase H, Barrett AJ, Woessner JR. Nomenclature and glossary of the matirx metalloproteinases. Matrix 1992;1(Suppl 1): 421-4.
5. Woessner FJR. The family of matrix metalloproteinases. Ann N Y Acad Sci 1994;732:11-21.
6. Borkakoti N. Matrix metalloproteinases: variations on a theme. Prog Biophys Mol Biol 1998;70:73-94.
7. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, De Carlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Bio Med 1993;4:197-250.
8. Kinoh H, Sato H, Tsunezuka Y, Takino T, Kawashima A, Okada Y, et al. MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci 1996;109:953-9.
9. Knauper V, Will H, López-Otin C, Smith B, Atkinson SJ, Stanton H, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: evidence that MT1-MMP and gelatinase A are able to generate active enzyme. J Biol Chem 1996;271:17124-31.
10. Baramova EN, Bajou K, Remade A, L'Hoir C, Krell HW, Weidle UH, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997;405:157-62.
11. Vissers MC, Winterbourn CC. Activation of human neutrophil gelatinase by endogenous serine proteases. Biochem J 1988;249:327-31.
12. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived-foams cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-9.
13. Heussen C, Dowle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecylsulfate and copolymerized substrate. Anal Biochem 1980;102:196-202.
14. Sawicki G, Salas E, Murat J, Mistza-Lane H, Radomski MW. Release of gelatinase B during platelet activation mediates aggregation. Nature 1997;386:616-9.
15. Jin CF, Mata M, Fink DJ. Rapid construction of deleted DNA fragments for use as internal standards in competitive PCR. PCR Methods Appl 1994;3:252-5.
16. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
17. Ray JM, Stetler-Stevenson WG. The role of metalloproteinases and their inhibitors in tumor, metastasis, and angiogenesis. Eur Respir J 1994;7:2062-72.
18. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastasic potential correlates with enzymatic degradation of basament membrane collagen. Nature 1980;284:67-8.
19. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413-7.
20. Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43:791-7.
21. Tryggvason K, Hoyhta M, Pyke M. Type IV collagenases in invasive tumors. Breat Cancer Res Treat 1993;24:209-18.
22. Schwartz G, Wang H, Lampen N, Altorki N, Kelsen D, Albino AP. Defining the invasive phenotype of proximal gastric cells. Cancer 1994;56:500-5.
23. Inoue T, Yashiro M, Nishimura S, Maeda K, Sawada T, Ogawa Y, et al. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advancced gastric cancer. Int J Mol Med 1999;4:73-7.
24. Ajisaka H, Fushida S, Yonemura Y, Miwa K. Expression of insulin-like growth factor-2, c-MET, matrix metalloproteinase-7 and MUC-1 in primary lesions and lymph node metastatic lesions of gastric cancer. Hepatogastroenterology 2001;48:1788-92.
25. Del Casar Lizcano JM, Vizoso Pineiro F, González-Sánchez LO, Martín Suárez A, Gava R, Cuesta Fernández E, et al. Expresión y significado clinico de la colagenasa-3 (MMP-13) en el cáncer gástrico. Gastroenterol Hepatol 2003;26:1-7.
26. Elnemr A, Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, et al. Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer. Gastric Cancer 2003;6:30-8.
27. Roeb E, Dietrich CG, Winograd R, Arnd M, Breuer B, Fass J, et al. Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer 2001;92:2680-91.
28. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002;86:1876-83.
29. Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, Fogt F, et al. Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer 2003;107:183-8.
30. Tutton MG, George ML, Eccles SA, Burton S, Swift SI, Abulafi AM. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 2003;107:541-50.
31. Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 2002;122:60-71.
32. Horiuchi S, Yamamoto H, Min Y, Adachi Y, Itoh F, Imai K. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol 2003;200:568-76.
33. Rivat C, Le Floch N, Sabbah N. Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion. FASEB J 2003;17:1721-3.
34. Tomita T, Iwata K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 1996;39:1255-64.
35. Yantiss RK, Bosenberg MW, Antonioli DA, Ozde RD. Utility of MMP-1, p53, E-cadherin, and collagen IV immunohistochemical stains in the differential diagnosis of adenomas with misplaced epithelium versus adenomas with invasive adenocarcinoma. Am J Surg Pathol 2002;26:206-15.
36. Yamashita K, Mon M, Shiraishi T, Shibuta K, Sugimachi K. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 2000;6:1169-74.
37. Ohashi K, Nemoto T, Nakamura K, Nemori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 2000;88:2201-9.
38. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001;85:383-92.
39. Maatta M, Sioni Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 2000;6:2726-34.
40. Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 2002;109:1437-44.
41. Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 2001;7:2344-6.
42. Miao X, Yu C, Tan W, Xiong P, Liang G, Lu W, et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 2003;63:3987-90.
43. Matsuoka T, Yashiro M, Sawada T, Ishikawa T, Ohira M, Hirakawa K. Effect of a matrix metalloproteinase inhibitor on a lymph node metastatic model of gastric cancer cells passaged by orthotopic implantation. J Exp Clin Cancer Res 2001;20:213-8.
44. Maki H, Hojo K, Tanaka H, Sawada TY, Maekawa R, Yoshioka T. Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11. Clin Exp Metastasis 2002;19:519-26.
45. Aparicio T, Kermorgant S, Dessirier V, Lewin MJ, Lehy T. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats. Carcinogenesis 1999;20:1445-51.
46. Oba K, Konno H, Tanaka T, Baba M, Kamiya K, Ohta M, et al. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166. Cancer Lett 2002;175:45-51.
47. Rosemurgy A, Harris J, Langleben A, Casper E, Goode S, Rasmussen H. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 1999;22:247-52.
48. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-7.
49. Meikle MC, Atkinson SJ, Ward RV, Murphy G, Reynolds JJ. Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interlukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodontal Res 1989;24:207-13.
50. Page RC. The pathobiology of periodontal diseases may affect systemic disease: inversion of paradigm. N Periodontol 1998;3:108-20.
51. Bailey CJ, Hembry RM, Alexander A, Irving MH, Grant ME, Shuttleworth CA. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994;47:113-6.
52. Pender S, Tickle S, Docherty A, Howie D, Wathen NC, MacDonald TT. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-90.
53. Pender S, Fell J, Chamow SM, Ashkenazi A, MacDonald TT. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinases production. J Immunol 1998;160:4098-103.
54. Baugh M, Perry M, Hollander A, Davies DR, Cross SS, Lobo AJ, et al. Matrix metalloproteinases levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117:814-22.
55. Von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000;47:63-73.
56. Heuschkel RB, MacDonald TT, Monteleone G, Bajaj-Elliott M, Smith JA, Pender SL. Imbalance of stromelysin 1 and TIMP 1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000:47:57-62.
57. Stallmach A, Chan CC, Ecker K-W, Feifel G, Herbst H, Schuppan D, et al. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 2000;47:415-22.
58. Tarlton JF, Whiting CV, Tunmore D, Bregenholt S, Reimann J, Claesson MH, et al. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a mourine model of colitis. Am J Pathol 2000;157:1927-35.
59. Medina C, Videla S, Radomski A, Radomski MW, Antolin M, Guarner F, et al. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol 2003;284:G116-G22.
60. Medina C, Videla S, Radomski A, Radomski MW, Antolin M, Guarner F, et al. Therapeutic effect of phenantroline in two rat models of inflammatory bowel disease. Scand J Gastroenterol 2001;36:1314-9.
61. Sykes AP, Bhogal R, Brampton C, Chander C, Whelan C, Parsons ME, et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 1999;13:1535-42.
62. Daum S, Bauer U, Foss HD, Wahnschaffe U, Schuppan D, Stein H, et al. Increased expression of mRNA for matrix metalloproteinases-1 and -3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease. Gut 1999;44:17-25.
63. Hovdenak N, Wang J, Sung CC, Kelly T, Fajardo LF, Hauer-Jensen M. Clinical significance of increased gelatinolytic activity in the rectal mucosa during external beam radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:919-27.